评论
打印
On Monday, a new paper had identified a possible barrier to using the revolutionary gene-editing tool CRISPR in humans.
周一，新论文发现在人类身上使用革命性基因编辑工具“CRISPR”有可能存在障碍。
The news sent the stocks of all three major CRISPR biotech firms tumbling in premarket trading.
该新闻出现使得三大“CRISPR”生物科技公司股价在盘前交易中暴跌。
They declined by as much as 11.9 percent.
他们的股价下跌了11.9%之多。
In recent years, CRISPR has been credited with the potential power to correct any number of devastating diseases.
近些年，“CRISPR”一直被认为拥有治愈各种可怕的疾病的潜在力量。
Researchers have used it to cure mice of deadly genetic conditions like hemophilia B, Lou Gehrig's disease, and Huntington's disease.
研究者使用该技术治愈了老鼠的致命性基因疾病，如乙型血友病，卢伽雷病和亨廷顿病。
In the U.S., the first human CRISPR trials are slated to begin this year.
美国首例人类“CRISPR”试验计划在今年开始进行。
译文属可可英语原创，未经允许，不得转载。
